Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy

Study Type	Interventional (Clinical Trial)
Sponsor Name	Abbvie
Disease type	Small Cell Lung Cancer
Disease Stage	IV
Clinical Status	Second Line
Phase	III
Intervention / Treatment	Rovalpituzumab Teserine / Topotecan
Research Site	Sacré Coeur
Investigator	Dr Kevin Jao
Coordinator	Anne-Marie Laliberté
Telephone number
Fax number
Study start date	23-Feb-17
Study end date	–
Trial Status	Recruiting